Browse > Article

A Case of Mucopolysaccharidosis Type 2 Diagnosed Early through Brain MRI  

Lee, Yoon kyoung (Departments of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Cho, Sung Yoon (Departments of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kim, Jinsup (Departments of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Huh, Rimm (Departments of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jin, Dong-Kyu (Departments of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Journal of The Korean Society of Inherited Metabolic disease / v.15, no.2, 2015 , pp. 87-92 More about this Journal
Abstract
Mucopolysaccharidosis (MPS) is an inherited disease entity associated with lysosomal enzyme deficiencies. MPS type 2, also known as Hunter syndrome, has a characteristic morphology primarily involving x-l inked recessive defects and iduronate-2-sulfatase gene mutation. The purpose of this case report is to provide important clues to help pediatricians identify Hunter syndrome patients earlier (i.e., before the disease progresses). A 30-month-old boy showed developmental delay and decreased speech ability. Physical examinations revealed a flat nose and extensive Mongolian spots. Brain magnetic resonance images (MRIs) showed bilateral multiple patchy T2 hyperintense lesions in the periventricular and deep white matter, several cyst-like lesions in the body of the corpus callosum, and diffuse brain atrophy, which were in keeping with the diagnosis. Based on these findings, the patient was suspected of having MPS. In the laboratory findings, although the genetic analysis of IDS (Iduronate-2-sulfatase) did not show any pathogenic variant, the enzymatic activity of IDS was not detected. We could confirm the diagnosis of MPS, because other sulfatases, such as ${\alpha}$-L-iduronidase, were detected in the normal range. Early enzymatic replacement therapy is essential and has a relatively good prognosis. Therefore, early diagnosis should be made before organ damage becomes irreversible, and brain MRIs can provide additional diagnostic clues to help distinguish the disorder.
Keywords
Mucopolysaccharidosis type 2; Iduronate-2-sulfatase; Brain MRI; Developmental delay;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Wraith JE, Scarpa M, Beck M, Beck M, Bodamer OA, Meirleir LD, et al. Mucopolysaccharidosistype II (Hunter syndrome) : a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-77.   DOI
2 Ahn SY, Lee Y, Jeon SY, Lim BK, Lee WS. A Case of Hunter Syndrome. Kor J Dermatol 2008;46:928- 32.
3 Lin SP, Chang JH, Lee-Chen GJ, Lin DS, Lin HY, Chuang CK. Detection of Hunter syndrome (Mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2- sulfatase gene defects in MPS II patients and carriers. Clin Chim Acta 2006;369:29-34.   DOI
4 Faragher MW, Stark RJ. Hunter syndrome complicated by hydrocephalus and an endogenous anticoagulant. J Clin Neurosci 1997;4:252-5.   DOI
5 Hunter C. A rare disease in two brothers. Proc R Soc Med 1917;10:104.
6 Hurler G. Uber einen Typ multipler Abartungen, vorwiegend am Skelettsystem. Z Kinderheilkd 1919; 24:220.
7 Mackusick VA, Kaplan D, Wise D, Hanley WB, Suddarth SB, Sevick ME. The genetic mucopolysaccharidosis. Medicine 1965;44:44.
8 Cho SY, Jin DK. Distribution of patients with mucopolysaccharidosis in east asia and current status and prospect for treatment 2013;13:81-8.
9 Downs AT, Crisp T, Ferretti G. Hunter's syndrome and oral manifestations : a review. Pediatr Dent 1995;17:98-100.
10 Cho SY, Huh R, Chang MS, Lee JE, Kwun YH, Maeng SH, et al. Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II. J Korean Med Sci 2014;29:254-60.   DOI
11 Sohn WY, Lee JH, Paik KH, Kwon EK, Kim AH, Jin DK. Clinical and laboratory features of korean mucopolysaccharidosies. Korean J Pediatr 2005;48: 1132-8.
12 Jurecka A, Krumina Z, Zuber Z, Rozdzynska- Swiatkowska A, Kloska A, Czartoryska B, Tylki- Szymanska A. Mucopolysaccharidosis Type II in Females and Response to Enzyme Replacement Therapy. Am J Med Genet A 2012;158A:450-4.   DOI
13 Gauri Shankar Shah, Tania Mahal, Subodh Sharma. Atypical clinical presentation of mucopolysaccharidosis type 2 : a case repot. Journal of Medical Case Reports 2010;4:154.   DOI
14 Akemi Tanaka a, Torayuki Okuyama b, Yasuyuki Suzuki, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan. Molecular Genetics and Metabolism 2012;107:513-20.   DOI
15 Lee S, Kim CS, Yang MK, Choi SJ, Lee BD, Park YO, et al. Clinical Experience of the Anesthetic Management of Mucopolysaccharidosis. Korean J Anesthesiol 2003;45:672-6.   DOI
16 Sohn WY, Lee JH, Paik KH, Kwon EK, Kim AH, Jin DK. Clinical and Laboratory Features of Korean Mucopolysaccharidoses (MPSs). Korean J Pediatrics 2005;48:1132-8.
17 Jin DK, Cho SY. 헌터증후군길잡이. 1st ed. Seoul: IMED Korea, 2014:147
18 Zafeirious DI, Batzios SP. Brain and Spinal MR Imaging Findings in Mucopolysaccharidosess: A Review. AJNR 2013;34:5-13.   DOI
19 Rasalkar DD, Chu WC, Hui J, Chu CM, Paunipagar BK, Li CK. Pictorial review of mucopolysaccharidosis with emphasis on MRI features of brain and spine. Br J Radiol 2011;84:469-77.   DOI